<![CDATA[Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer ]]>
Treatment with zanidatamab-hrii (Ziihera) produced clinically meaningful benefits among patients with HER2-amplified, locally advanced or metastatic, previously treated biliary tract cancer (BTC), according to final results from the phase 2 HERIZON-BTC-01 …